Home » Thought Leadership

Thought Leadership

Read our insights and commentary about pharmaceutical industry news and healthcare innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 32 posts
CBPartners' Pharma Take-Away: AMARIN's VASCEPA patent loss: is it obvious(ness)?
March 8, 2021 | Podcasts

USA Policy Expectations for a New Administration

This episode, which kicks off season two of CBPartners’ Pharma Take-away, discusses the possible evolution of healthcare and healthcare policy in the United States, and explores the changes we may expect over the next few years as a result of the presidential election party transition.

KAISER’s recent systemic integration of digital health therapeutics (DTx) into the treatment paradigm for behavioral health
February 19, 2021 | Infographics

KAISER Integrates DTx Into the Behavioral Health Treatment Paradigm at No Extra Cost After a Clinician Referral

KAISER’s recent systemic integration of digital health therapeutics (DTx) into the treatment paradigm for behavioral health concerns is a step towards modernizing healthcare and represents a very structured approach to real-world data generation.

September 22, 2020 | Blog

CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA

CAR-Ts offer a significant clinical benefit for patients, however their full potential is currently limited by later line use at sites that are mostly academic centers, combined with significant logistical barriers. In CBPartners’ latest thought leadership article, our healthcare consultants look further into these barriers before assessing the opportunities that could bring CAR-Ts into earlier lines of treatment across oncology.

September 17, 2020 | Blog

Hitting the Mark: Lessons Learned From Blockbuster Drugs That Missed or Exceeded Analyst Expectations

Pharmaceutical products can both exceed and fall short of blockbuster sales expectations by considerable margins which can be a result of a number of reasons. Some of these include the value of first-to-market dynamics, supporting real-world evidence to gain a competitive edge, and continual investment in trials for follow-on indications to improve life cycle management.

July 6, 2020 | Blog

What’s Next for Alzheimer’s Disease?

Basic science has been redeployed to establish a new understanding of Alzheimer's Disease, focusing on novel biomarkers and cutting-edge therapeutic approaches to slow or reverse disease progression, where the amyloid beta theory has otherwise failed